Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $627.00 at Bank of America

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lifted by Bank of America from $543.00 to $627.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an underperform rating on the biopharmaceutical company’s stock.

Several other brokerages have also commented on REGN. Citigroup increased their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price target on the stock. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $813.78.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $652.91 on Wednesday. The company has a current ratio of 4.82, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $69.20 billion, a PE ratio of 15.63, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The business’s 50-day moving average price is $579.44 and its 200-day moving average price is $564.03. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $935.86.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the company earned $12.46 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. PGGM Investments lifted its stake in shares of Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares during the period. Founders Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares during the period. Sepio Capital LP lifted its stake in shares of Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock valued at $16,255,000 after purchasing an additional 955 shares during the period. Finally, Generate Investment Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $6,300,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.